Our findings are important for patients suffering from T1DM, as well as for treating physicians, since they indicate that NAFLD as well as cardiac steatosis is no clinically relevant long-term consequence of insulin therapy. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.